Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas

NCT02900716 is registered in ClinicalTrials.gov with Zhejiang DTRM Biopharma as lead sponsor.

NCT NCT02900716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02900716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Lead sponsor
Zhejiang DTRM Biopharma
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2016
Completion date
November 23, 2020
Enrollment
48 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, chronic lymphocytic leukemia